AsianScientist (Aug. 18, 2015) – The crystal structure of an enzyme used in the manufacturer of the diabetes drug sitagliptin sheds light on how this important class of enzymes recognize their substrates. The research, published in Scientific Reports, could help further the design of novel biocatalysts for industrial production of chiral amine compounds, crucial building blocks in the synthesis of some pharmaceutical drugs.
Pure chiral amines are crucial building blocks in the synthesis of some pharmaceutical drugs, agrochemicals and other chemical compounds. Amine transaminases (ATAs) are the focus of increasing attention as useful tools for efficient chiral-amine production. In particular, R-stereospecific ATA (R-ATA), a type of ATA that produces only R-chiral amines, has great commercial value.
In 2010, two US pharmaceutical companies created a variant of an R-ATA allowing industrial-scale synthesis of sitagliptin, a medicine for type-2 diabetes. The improved enzyme gave a 53 percent increase in daily production volume and a 19 percent reduction in total cost, as compared to the chemical approach conventionally used to synthesize sitagliptin.
However, how the industrially-important enzyme R-ATA recognized its substrate and other details remained unclear.
The research group of Professor Masaru Tanokura at the Graduate School of Agricultural and Life Sciences of the University of Tokyo, in collaboration with Biotechnology and Development Laboratories of Kaneka Corporation, determined the crystal structures of R-ATA from a bacteria that lives in soil and other materials, Arthrobacter sp. KNK168 (Ab-R-RTA).
One unique characteristic of ATAs is that they recognize two different substrates in the same active site, and it was found that the active-site residue arginine (Arg138) functions on both substrates. Moreover, the structures of an artificial R-ATA and the G136F mutant of Ab-R-ATA (created by substituting the 136th base glycine for phenylalanine) revealed that a loop near the catalytic site was the target site that allowed the change in substrate specificity.
“These findings should lead to the rational design of R-ATAs based on this structural information to develop novel biocatalysts useful for the production of a diverse range of chiral amine compounds. This would accelerate the industrial uses of chiral-amine synthesis using R-ATAs,” said Tanokura.
The article can be found at: Guan et al. (2015) A New Target Region for Changing the Substrate Specificity of Amine Transaminases.
Source: The University of Tokyo.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.